Literature DB >> 21056908

Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

Henry L Chang1, Rafael Pieretti-Vanmarcke, Fotini Nicolaou, Xianlin Li, Xiaolong Wei, David T MacLaughlin, Patricia K Donahoe.   

Abstract

OBJECTIVE: Given the fact that Mullerian Inhibiting Substance (MIS) causes complex remodeling of the urogenital ridge and regression of the Mullerian ducts during male embryonic development, we examined whether MIS could affect similar cell properties such as migration and invasion that could contribute ultimately to micro-metastasis of cancers arising from Mullerian tissues. MIS receptor expressing cell lines found to be invasive and migratory in vivo are examined in an in vivo assay that is cost-effective.
METHODS: We designed in vitro and in vivo experiments to determine if MIS inhibited the movement of cancer lines IGROV-1, HEp3, MDA-MB-231, and HT1080 in cell culture invasion/migration chamber assays and in chick embryo metastasis assays.
RESULTS: MIS, at concentrations below those that inhibit cell proliferation, blocked in vitro invasion and in vivo migration of epithelial cancer cells that express the MIS receptor.
CONCLUSIONS: While our laboratory has previously established MIS as an inhibitor of cancer cell proliferation using in vitro assays and in vivo xenografts, we now show that MIS can also inhibit in vivo tumor migration.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056908      PMCID: PMC3008816          DOI: 10.1016/j.ygyno.2010.09.017

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  42 in total

1.  Chick pulmonary Wnt5a directs airway and vascular tubulogenesis.

Authors:  Maria Loscertales; Amanda J Mikels; Jimmy Kuang-Hsein Hu; Patricia K Donahoe; Drucilla J Roberts
Journal:  Development       Date:  2008-02-27       Impact factor: 6.868

2.  Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor.

Authors:  L Gouédard; Y G Chen; L Thevenet; C Racine; S Borie; I Lamarre; N Josso; J Massague; N di Clemente
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

3.  Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.

Authors:  P T Masiakos; D T MacLaughlin; S Maheswaran; J Teixeira; A F Fuller; P C Shah; D J Kehas; M K Kenneally; D M Dombkowski; T U Ha; F I Preffer; P K Donahoe
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

4.  DiI analysis of cell migration during müllerian duct regression.

Authors:  H B Austin
Journal:  Dev Biol       Date:  1995-05       Impact factor: 3.582

5.  Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family.

Authors:  W W He; M L Gustafson; S Hirobe; P K Donahoe
Journal:  Dev Dyn       Date:  1993-02       Impact factor: 3.780

6.  Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.

Authors:  Xiaolong Wei; David Dombkowski; Katia Meirelles; Rafael Pieretti-Vanmarcke; Paul P Szotek; Henry L Chang; Frederic I Preffer; Peter R Mueller; Jose Teixeira; David T MacLaughlin; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-15       Impact factor: 11.205

7.  Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone.

Authors:  N di Clemente; C Wilson; E Faure; L Boussin; P Carmillo; R Tizard; J Y Picard; B Vigier; N Josso; R Cate
Journal:  Mol Endocrinol       Date:  1994-08

8.  The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.

Authors:  Jae Yen Song; Keun Young Chen; Sue Yeon Kim; Mee Ran Kim; Ki Sung Ryu; Jung Ho Cha; Chang Suk Kang; David T MacLaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

9.  Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct.

Authors:  Akihiro Fujino; Nelson A Arango; Yong Zhan; Thomas F Manganaro; Xianlin Li; David T MacLaughlin; Patricia K Donahoe
Journal:  Dev Biol       Date:  2008-11-05       Impact factor: 3.582

10.  A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the müllerian duct.

Authors:  W M Baarends; M J van Helmond; M Post; P J van der Schoot; J W Hoogerbrugge; J P de Winter; J T Uilenbroek; B Karels; L G Wilming; J H Meijers
Journal:  Development       Date:  1994-01       Impact factor: 6.868

View more
  15 in total

1.  Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.

Authors:  Tim N Beck; Vladislav A Korobeynikov; Alexander E Kudinov; Rachel Georgopoulos; Nehal R Solanki; Magda Andrews-Hoke; Timothy M Kistner; David Pépin; Patricia K Donahoe; Emmanuelle Nicolas; Margret B Einarson; Yan Zhou; Yanis Boumber; David A Proia; Ilya G Serebriiskii; Erica A Golemis
Journal:  Cell Rep       Date:  2016-07-07       Impact factor: 9.423

2.  Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.

Authors:  E Basal; T Ayeni; Q Zhang; C Langstraat; P K Donahoe; D Pepin; X Yin; E Leof; W Cliby
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

3.  Reduced serum levels of anti-Müllerian hormone in females with inherited bone marrow failure syndromes.

Authors:  Martha M Sklavos; Pamela Stratton; Neelam Giri; Blanche P Alter; Sharon A Savage; Ligia A Pinto
Journal:  J Clin Endocrinol Metab       Date:  2014-11-18       Impact factor: 5.958

4.  Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Aurelio Barricarte; Louise A Brinton; Brian L Egleston; Roni T Falk; Renée T Fortner; Kathy J Helzlsouer; Yutang Gao; Annika Idahl; Rudolph Kaaks; Vittorio Krogh; Melissa A Merritt; Eva Lundin; N Charlotte Onland-Moret; Sabina Rinaldi; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Carlotta Sacerdote; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley S Tworoger; Kala Visvanathan; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Joanne F Dorgan
Journal:  Int J Cancer       Date:  2017-10-04       Impact factor: 7.396

5.  Anti-Müllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor.

Authors:  Tiansong Zhang; Linhao Deng; Qian Xiong; Shujun Su; Jian Gu
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

Review 6.  Ovarian cancer stem cell markers: prognostic and therapeutic implications.

Authors:  Daniela Burgos-Ojeda; Bo R Rueda; Ronald J Buckanovich
Journal:  Cancer Lett       Date:  2012-02-11       Impact factor: 8.679

Review 7.  Regulation of the ovarian reserve by members of the transforming growth factor beta family.

Authors:  Stephanie A Pangas
Journal:  Mol Reprod Dev       Date:  2012-09-11       Impact factor: 2.609

8.  Reduced migration of Ishikawa cells associated with downregulation of aquaporin-5.

Authors:  Xiu Xiu Jiang; Kai Hong Xu; Jun Yan Ma; Yong Hong Tian; Xiao Yan Guo; Jun Lin; Rui Jin Wu
Journal:  Oncol Lett       Date:  2012-05-30       Impact factor: 2.967

9.  Serum anti-mullerian hormone and all-cause mortality in men.

Authors:  Rehan Qayyum; Sana Akbar
Journal:  Endocrine       Date:  2016-08-08       Impact factor: 3.633

10.  Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis.

Authors:  Noor A Lokman; Alison S F Elder; Carmela Ricciardelli; Martin K Oehler
Journal:  Int J Mol Sci       Date:  2012-08-10       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.